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ABSTRACT
In 14 women, aged 47.2 6 10.5 yr, bilaterally adrenalectomized for
Cushing’s disease 13.6 6 7.7 yr before, all receiving conventional
doses of glucocorticoid and mineralocorticoid substitution, body com-
position was studied with regard to body fat, body fat distribution,
fat-free mass, and bone mineral density. The data were compared
with those of 14 healthy women of similar age, body mass index, and
menopausal state. Five different body composition measurement
methods were compared, i.e. body densitometry by underwater weigh-
ing (UWW), total body water measurement by deuterium dilution
(D2O dilution), dual energy x-ray absorptiometry (DXA), bioelectrical
impedance spectrometry (BIS), and skinfold measurements, using a
four-component model (4C-model) as the reference method.
In the patients the percent body fat was significantly higher than
that in the controls as determined by all methods, whereas fat-free
mass was significantly lower when measured with the 4C-model,
UWW, D2O dilution, DXA, or BIS. Measured by DXA, the percent
trunk fat, estimated as [fat mass of the trunk (g)/total fat mass (g)]
3 100%, was significantly higher in the patients than in the controls
(39.3 6 6.4% and 29.9 6 7.8%, respectively; P , 0.001). Measured by
DXA, there was no difference in total bone mineral density between
the groups. Differences between the 4C-model, UWW, D2O dilution,
and DXA for determination of percent body fat were rather small.
Skinfold measurements and BIS results, however, deviated substan-
tially from those obtained using the 4C-model.
The study indicates that adrenalectomized patients receiving con-
ventional glucocorticoid substitution have increased body fat percent-
ages with a centripetal fat distribution and lowered fat-free mass, but
normal bone mineral density. Furthermore, the study indicates that
for clinical practice, DXA, D2O dilution, UWW, and the 4C-model can
be used for determination of body composition in this patient group,
whereas the more convenient bedside methods, BIS and skinfold
measurements, did not give reliable results. We suppose that glu-
cocorticoid overreplacement in adrenalectomized patients might be
the cause of their abnormal body composition, although GH deficiency
after pituitary surgery could have played a contributory role in some
of the patients. (J Clin Endocrinol Metab 84: 3991–3999, 1999)
BEFORE THE era of transsphenoidal pituitary surgery,total adrenalectomy has been widely used to treat
pituitary-dependent Cushing’s syndrome. Today, total ad-
renalectomy is no longer the primary therapy for Cushing’s
disease, but there still remain patients in whom bilateral
adrenalectomy is needed for cure of the disease, especially
when pituitary surgery was unsuccessful. It is the clinical
impression that patients bilaterally adrenalectomized for
treatment of Cushing’s disease have an abnormal body com-
position. Body composition, however, has never been stud-
ied with objective methods in this group of patients.
A variety of methods for measuring human body compo-
sition are available. Most of these methods are based upon
the two-component model in which the body consists of two
chemically distinct compartments, the fat and fat-free
masses. In this model it is assumed that the fat-free com-
partment has a density of 1.1 g/cc at 37 C and a water content
of 0.73 L/kg, whereas fat, which is supposed to be anhy-
drous, has a density of 0.9 g/cc at 37 C (1). Examples of
methods using the two-component model are measurement
of whole body density by underwater weighing (UWW),
measurement of total body water by deuterium dilution
(D2O dilution), dual energy x-ray absorptiometry (DXA),
bioelectrical impedance spectrometry (BIS), and measure-
ment of skinfold thicknesses.
In the four-component model (4C-model) the human body
is divided into four chemically distinct compartments: water,
protein, bone mineral, and fat. This model overcomes un-
certainties concerning the hydration fraction of the fat-free
mass (FFM) and segregates protein from mineral. Therefore,
this model circumvenes the need for some of the assumptions
inherent to the two-component model regarding proportions
and densities of different components of the FFM (2). One of
the most reliable methods for determining body composition
is that of Füller et al. (2), in which a four-component model
is used, which combines the results of densitometry by UWW
with those of measurement of bone mineral content by DXA,
and total body water assessment by D2O dilution (2, 3). The
regional distribution of body fat is a critical variable to con-
sider in the clinical assessment of (former) Cushing’s pa-
tients, as accumulation of fat in the central part of the body
is associated with an increased incidence of cardiovascular
morbidity and mortality (4).
In the present study we obtained body composition data,
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such as body fat, body fat distribution, FFM, and bone min-
eral density (BMD), in a group of women bilaterally adre-
nalectomized for Cushing’s disease, all receiving conven-
tional glucocorticoid and mineralocorticoid substitution, and
we compared these data with those of healthy women of
similar age, body mass index, and menopausal state. We
compared the relatively costly and complicated mechanistic
methods (UWW, D2O dilution, and DXA) with the fast and
inexpensive descriptive bedside body composition measure-




Fourteen women, aged 47.2 6 10.5 yr (mean 6 sd; range, 28–60 yr)
bilaterally adrenalectomized for pituitary-dependent Cushing’s syn-
drome 13.6 6 7.7 yr earlier (range, 2–27 yr) were studied. Clinical
characteristics and medical therapy of these 14 patients are summarized
in Table 1. Eight of them were postmenopausal, and 6 were premeno-
pausal at the time of the study. Before adrenalectomy 7 of the 14 patients
had undergone unsuccessful pituitary surgery, and 1 had undergone
transsphenoidal cryocoagulation of the pituitary. Two others had un-
dergone pituitary surgery because of Nelson’s syndrome after adrenal-
ectomy, 18 and 11 yr before this study; in the latter patient pituitary
surgery was followed by radiotherapy with a total dose of 46 Gy. All
patients had conventional doses of glucocorticoid (cortisone acetate, n 5
10; hydrocortisone, n 5 1; prednisone, n 5 2; dexamethasone, n 5 1) and
mineralocorticoid substitution (9a-fluorohydrocortisone, all). For com-
parison, the doses of the glucocorticoids were converted to hydrocor-
tisone equivalents (30 mg hydrocortisone 5 37.5 mg cortisone acetate 5
7.5 mg prednisone 5 0.75 mg dexamethasone). The daily dose of hy-
drocortisone equivalent at the time of the study was 27.3 6 7.9 mg
(mean 6 sd), and that of 9a-fluorohydrocortisone was 0.11 6 0.06 mg.
At the time of the study four patients were adequately substituted with
levothyroxine because of secondary hypothyroidism, seven used estro-
gens (as oral contraception or as replacement therapy), and two were
treated with desmopressin because of diabetes insipidus. To evaluate the
presence of GH deficiency, in 13 of the 14 patients a standard arginine
provocation test (0.5 g/kg arginine-HCl; maximal dose, 30 g) was per-
formed. Peak plasma GH levels after arginine are given in Table 1. None
of the patients had received GH substitution therapy. Three patients
were treated for hypertension. Fourteen healthy female controls, aged
46.8 6 11.1 yr (mean 6 sd; range, 26–59 yr) and matched with individual
patients for age, body mass index (BMI), and menopausal state, were
recruited. Two of them used estrogens as oral contraception. Patients
and controls were well matched for age, height, weight, and BMI, re-
spectively (Table 2).
The study was approved by the ethics committee of the University
Hospital of Nijmegen. All subjects gave informed consent after expla-
nation of the aims and methods of the study.
Determination of percent body fat (%BF) and FFM using
the two-component model
Measurement of whole body density by UWW. After measuring body
density by UWW it is possible to determine body fat and FFM from
the measured whole body density (1). This technique uses determi-
nation of body volume according to Archimedes’ principle, which
states that the volume of an object submerged in water equals the
volume of water the object displaced. If one measures weight in air
and weight in water, the difference, corrected for the density of the
water corresponding to the water temperature at the time of the
underwater weighing, is the apparent body volume. Patients and
controls, therefore, were submerged in water, dressed in swimwear,
for measuring weight in water and body volume. The measurement
was performed in the fasted state during tidal volume respiration,
and correction was made for residual lung volume during submer-
sion. Residual lung volume was measured with the helium dilution
technique using a lung volume meter.
Measurement of total body water (TBW) by D2O dilution. Measurement of
TBW is a method that allows determination of body fat and FFM,

















1 Pre 25 No 59 CA (15.0 mg) F (0.06 mg) Ethinyl estradiol (30
mg)/desogestrel (150 mg)
2 Pre 17 No 21 CA (37.5 mg) F (0.09 mg)
3 Post 21 No 4 CA (25.0 mg) F (0.13 mg) b-Blocker
4 Post 14 Before ADX NA CA (50.0 mg) F (0.19 mg) Levothyroxin, a-blocker
5 Pre 9 Before ADX 23 D (0.5 mg) F (0.19 mg) Ethinyl estradiol (30
mg)/desogestrel (150 mg)
Desmopressin
6 Pre 6 Before ADX 3 HC (20.0 mg) F (0.19 mg) Ethinyl estradiol (30
mg)/levonorgestrel (150 mg)
7 Post 10 Before ADX 10 CA (37.5 mg) F (0.09 mg) Estradiol (1 mg)
8 Post 27 After ADX ,2 CA (37.5 mg) F (0.06 mg) Levothyroxin
9 Post 16 No 11 CA (37.5 mg) F (0.06 mg) Conjugated estrogen (0.625 mg)/
medroxyprogesteroneacetate
(10 mg)
10 Post 27 Cryocoagulation 11 P (5.0 mg) F (0.06 mg) Transdermal estradiol (50 mg)/
before ADX medroxyprogesteroneacetate
(10 mg)
11 Pre 8 Before ADX 22 CA (37.5 mg) F (0.10 mg) Desmopressin
12 Post 15 Before ADX 7 P (7.5 mg) F (0.09 mg)
13 Pre 2 Before ADX ,2 CA (37.5 mg) F (0.19 mg) Levothyroxin, ethinyl estradiol
(30 mg)/levonorgestrel (150
mg), ACE inhibitor
14 Post 16 After ADX 1
RT
,2 CA (50.0 mg) F (0.05 mg) Levothyroxin
ADX, Bilateral adrenalectomy; RT, pituitary radiotherapy; CA, cortisone acetate; D, dexamethasone; HC, hydrocortisone; P, prednisone; F,
9-a-fluorohydrocortisone; NA, not available.
a Doses are per day.
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assuming that water is not present in stored fat and that water occupies
a relatively fixed fraction (73.2%) of the FFM (5, 6). TBW was determined
by D2O dilution, as described previously (7). Before the intake of a single
oral dose of a known amount of deuterium, a urine sample was taken
for deuterium (background) measurement. After an overnight equili-
bration period of 10 h (8), another urine sample was taken for deuterium
(enriched) measurement. Subjects did not eat or drink between the time
the deuterium was taken and the enriched urine samples were obtained.
Deuterium in urine was measured by mass spectrometry (7).
DXA. Total bone mineral content (TBMC) and soft tissue composition of
the body were measured with dual energy x-ray absorptiometry (model
DPX, Lunar Corp., Madison, WI) as described previously (9). We used
the medium scan speed (80 mm/s) with a resolution of 4.8 3 9.6 mm.
For determination of soft tissue composition, total soft tissue (grams), fat
tissue (grams), lean tissue (grams), and bone mineral content (grams)
were measured in the total body and in the trunk. Moreover, total BMD
(TBMD; grams per cm2) was calculated using Lunar Corp. software
(version 1.3z).
BIS. With bioelectrical impedance measurements of the body at different
frequencies (BIS) it is possible to discriminate between the extracellular
water compartment (ECW) and the intracellular water compartment
(ICW) of the body, as tissue impedance at low frequencies is highly
correlated with the ECW and at high frequencies with the total body
water compartment (TBW) (10). The prediction of ECW and TBW using
the impedance of ECW and TBW depends on the underlying theory. We
used the general mixture theory based on emulsion sciences. This theory
includes properties of both the conducting material and the noncon-
ducting material in the suspension. An extensive explanation of this
theory is described by De Lorenzo et al. (10) as well as by Hanai (11). FFM
can be estimated from the results of BIS, assuming a fixed hydration of
the FFM of 0.73 L/kg. In patients and controls BIS was measured with
a Xitron 4000 Multi-Frequency Bio-Impedance Analyzer (Xitron Tech-
nologies, San Diego, CA) at frequencies of 5–500 kHz, as described
previously (10, 12). A tetrapolar arrangement of gel electrodes was used,
placed on hand, wrist, ankle, and foot at the right side of the body.
Skinfold thicknesses. Skinfold thicknesses were measured to the nearest
0.2 mm at four sites, i.e. biceps, triceps, subscapular, and suprailiac, with
a Holtain Ltd. caliper as described previously (1). Because body density
is not linearly related to sc fat mass, mathematical transformation of the
sum of skinfold thicknesses and correction for gender and age was
performed as described by Durnin and Womersley (13) for prediction
of %BF.
Determination of %BF and FFM using the 4C-model
Body composition was also estimated by the 4C-model according to
Füller, combining the measurements of body density (UWW), total body
water (D20 dilution), and bone mineral content (DXA). Classical two-
compartment models (fat and FFM), such as underwater weighing, are
limited by assumptions regarding the constancy of composition of the
FFM. The 4C-model (fat, water, protein, and mineral), which is based on
measurements obtained from densitometry, D2O dilution, and DXA,
overcomes uncertainties concerning the hydration of the FFM and bone
mineral content. The 4C-model incorporates direct measurement of
TBMC, as well as the established measurements of body density and
total body water. Densities of fat, protein, and TBMC are still assumed
as well as the ratio of osseous to nonosseous mineral. From this de-
scription it is evident that the calculations of body fat by UWW and D2O
dilution are not completely independent in the 4C-model. Differences in
outcome depend to a large extent on deviations from reference values
with respect to the hydration of FFM and to the bone mineral fraction
of FFM.
Total body fat was calculated according to the formula: fat (kg) 5
2.747 BV 2 0.710 TBW 1 1.460 TBMC 2 2.050 Wt, where BV is body
volume in liters (from UWW), TBW is total body water volume in liters
(from D2O dilution), TBMC is total bone mineral content in kilograms
(from DXA), and Wt is body weight in kilograms (2).
The density of the FFM was calculated according to the formula: DFFM
5 (0.710 TBW 1 3.050 Wt 2 2.747 BV 2 1.460 TBMC)/(0.788 TBW 1
2.276 Wt 2 2.050 BV 2 1.621 TBMC; the abbreviations TBW, Wt, BV, and
TBMC are defined above (2).
The hydration fraction of the FFM was calculated from the mass of
TBW (from D2O dilution) and total body FFM, obtained from the 4C-
model, according to the formula: hydration fraction 5 TBW/(0.715 TBW
1 3.070 Wt 2 2.765 BV 2 1.469 TBMC); the abbreviations TBW, Wt, BV,
and TBMC are defined above (2).
Determination of percent trunk fat (%TF)
We defined the fat mass of the trunk as the sc and the intraabdominal
fat mass of the thoracic and abdominal parts of the body. The %TF was
estimated as [fat mass of the trunk (g)/total fat mass (g)] 3 100%, as
measured with DXA as described above.
Statistical analysis
Wilcoxon’s signed rank test was used to test the significance of dif-
ferences between adrenalectomized patients and matched controls (P).
Spearman rank correlation coefficients were used to test relations be-
tween body fat compartments measured by different methods (P*).
Stepwise regression analysis was used to determine the relationships
between factors supposed to be related to body fat distribution. For
assessing the agreement between different methods, the bias and limits
of agreement (error) between the different methods were calculated
according to the method described by Bland and Altman (14). All data
are expressed as the mean 6 sd.
TABLE 2. Physical characteristics of the 14 adrenalectomized women and their controls
Subject no.
Adrenalectomized patients Controls
Age (yr) Ht (m) Wt (kg) BMI
(kg/m2)
Age (yr) Ht (m) Wt (kg) BMI
(kg/m2)
1 44 1.59 59.7 23.6 40 1.63 56.4 21.2
2 47 1.68 71.4 25.3 51 1.62 74.3 28.3
3 55 1.62 76.4 29.1 53 1.63 76.0 28.6
4 57 1.62 71.0 27.1 59 1.62 70.7 26.9
5 28 1.57 62.9 25.5 26 1.70 68.4 23.7a
6 35 1.75 62.2 20.3 37 1.75 59.6 19.4
7 55 1.61 61.2 23.6 57 1.58 55.0 22.0
8 51 1.71 71.6 24.5 48 1.70 75.8 26.2
9 52 1.64 63.2 23.5 55 1.63 65.1 24.5
10 58 1.70 69.1 23.9 58 1.61 64.1 24.7
11 35 1.63 54.3 20.4 34 1.67 55.2 19.8
12 60 1.66 70.3 25.5 57 1.69 72.1 25.3
13 33 1.58 57.5 23.0 31 1.70 59.5 20.6a
14 51 1.65 74.7 27.4 49 1.66 70.0 25.4
Mean (SD) 47.2 (10.5) 1.64 (0.05) 66.1 (6.8) 24.5 (2.5) 46.8 (11.1) 1.66 (0.05) 65.9 (7.7) 24.0 (3.0)
a Two of the controls used estrogens.
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Results
Percent body fat and FFM
As shown in Table 3, the %BF in the patients was signif-
icantly higher than in the controls, regardless of the method
used. Figure 1A shows that the %BF, as calculated by the
4C-model, was higher in the adrenalectomized patients than
in their control subjects. FFM in patients was significantly
lower than that in controls when measured with the 4C-
model, UWW, D2O dilution, DXA, or BIS. Skinfold measure-
ment failed to distinguish the difference in FFM between
both groups. In Fig. 1B the results of FFM, calculated by the
4C-model, are given for the individual patient-control pairs.
The hydration of the FFM in the patients (0.77 6 0.02 L/kg;
range, 0.73–0.80) was not different from that in controls
(0.76 6 0.01 L/kg; range, 0.74–0.78). There was no difference
in %BFDXA (39.3 6 5.2% and 39.7 6 3.5%, respectively) or in
FFMDXA (40.8 6 3.1 and 38.2 6 3.5 kg, respectively) between
patients with peak plasma GH levels after arginine provo-
cation of 10 mU/L or less and patients with GH levels greater
than 10 mU/L. Using a cut-off level for peak plasma GH of
15 mU/L after arginine provocation, there was also no dif-
ference in %BFDXA (38.9 6 4.6% and 40.9 6 3.8%, respec-
tively) or in FFMDXA (40.9 6 2.8 and 36.6 6 3.0 kg, respec-
tively) between the group with the lower and that with the
higher GH levels.
Regional fat distribution
Measured by DXA, the %TF in the patients was signifi-
cantly higher than that in the controls (39.3 6 6.4% and 29.9 6
7.8%, respectively; P , 0.001). In all patient-control pairs,
except one, %TF was higher in the patient than in the control
subject (Fig. 1C). There was no statistically significant dif-
ference in %TF (53.0 6 4.8% and 48.2 6 7.0%, respectively)
between patients with a GH level of 10 mU/L or less and
patients with a GH level greater than 10 mU/L after arginine
provocation or between patients with a GH level of 15 mU/L
or less and patients with a GH level greater than 15 mU/L
(52.8 6 4.8% and 46.0 6 5.7%, respectively). There was a
statistically significant correlation between %TF and %BF in
both patients and controls (r 5 0.44; P* , 0.02). However, in
a stepwise regression including the adrenalectomized state
and %BF as independent variables, only the adrenalecto-
mized state (as a dummy variable) appeared to be included
(P , 0.005), whereas %BF did not, stressing the difference
between the adrenalectomized patients and the controls with
respect to body fat distribution [%TF/%BF 5 7.89 3 D 1
0.1 3 %BFDXA 1 38.71; (D 5 dummy variable for the adre-
nalectomized state)].
BMD
DXA measurement showed no difference in total BMD
between patients and healthy controls (Table 3 and Fig. 1D)
and no statistically significant correlation between BMD and
%BF or %TF.
Comparison of the different body composition methods
For comparison of the methods we pooled the data from
patients and controls. To obtain information about the agree-
ment of two different methods, we plotted the difference
between the two methods against their mean (14). The 4C-
model served as the reference method. The comparisons
revealed no significant correlations between the differences
in %BF between the 4C-model and the mechanistic methods
(UWW, D2O dilution, or DXA), on the one hand, and the size
of the measurement, on the other hand, whereas those from
the descriptive methods (BIS or skinfolds) were significantly
negatively related to the average %BF (Fig. 2, A–E, and Table
4). The bias of the 4C-model with the methods UWW and
DXA, estimated by the average difference between methods,
was not significantly different from zero. The sd of the dif-
ferences between the 4C-model and DXA, however, was
relatively high. The bias of the 4C-model with D2O dilution
was greater (23.2%), but the error between both methods
was relatively small (2 sd, 2.4%). In the patient group only,
the bias of the 4C-model with skinfold measurements was
29.9%, and the error between both methods was 6.6%,






(mean 6 SD) P value
%BF
UWW (%) 11 41.7 6 5.6 31.1 6 7.5 ,0.005
D2O dilution (%) 12 39.8 6 4.6 28.8 6 6.5 ,0.005
DXA (%) 14 39.6 6 4.2 31.7 6 7.4 ,0.005
4C model (%) 11 42.4 6 4.5 31.7 6 6.7 ,0.005
BIS (%) 14 45.9 6 3.6 39.1 6 4.1 ,0.005
Skinfolds (%) 14 33.6 6 4.1 30.5 6 3.9 ,0.05
FFM
UWW (kg) 11 37.5 6 2.4 43.7 6 3.5 ,0.01
D2O dilution (kg) 12 39.1 6 3.1 45.7 6 2.8 ,0.005
DXA (kg) 14 39.8 6 3.4 44.5 6 2.2 ,0.005
4C model (kg) 11 37.1 6 2.5 43.3 6 2.8 ,0.01
BIS (kg) 14 35.6 6 3.1 39.9 6 3.6 ,0.01
Skinfolds (kg) 14 43.7 6 3.2 45.6 6 4.3 NS
Hydration of FFM (L/kg) 11 0.77 6 0.02 0.76 6 0.01 NS
TBMD DXA (g/cm2) 14 1.09 6 0.09 1.11 6 0.06 NS
UWW, Underwater weighing; D2O dilution, deuterium dilution method; DXA, dual energy x-ray absorptiometry; 4C model, four-component
model; BIS, bioelectrical impedance spectrometry; skinfolds, skinfold measurements.
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whereas the bias of the 4C-model with BIS was not
significant.
Discussion
In a group of 14 women adrenalectomized for Cushing’s
disease, conventionally substituted with gluco- and miner-
alocorticoids during periods up to 27 yr, body composition
differed impressively from that in control women matched
for age, body mass index, and menopausal state. The %BF
measured by the 4C-model as well as by five other methods
was significantly higher in the former Cushing’s patients.
Correspondingly, FFM, an indicator of muscle mass, was
significantly lower (;10%) in the adrenalectomized patients.
In the patients body fat distribution was also significantly
different from that in controls, with higher percentages of
truncal fat in the adrenalectomized patients.
To determine which body composition methods give re-
liable results in this specific patient group, we compared five
different methods using the 4C-model of Füller (2) as the
reference method. For determination of %BF, the differences
between the 4C-model and the mechanistic methods (UWW,
D2O dilution, and DXA) were not large. Of these methods the
average difference was highest between the D2O dilution
method and the 4C-model (23.2%). The relatively low %BF
found with the D2O dilution method can be explained by the
rather high hydration of FFM we found in this study. On the
FIG. 1. A and B, %BF (A) and FFM (B), calculated by the 4C-model of Füller in 11 female adrenalectomized patients vs. %BF and FFM in their
individual controls matched for age, sex, BMI, and menopausal state. C, %TF, defined as fat mass of the trunk (grams )/total fat mass (grams)
measured by DXA, in 14 female adrenalectomized patients vs. %TF in their individual controls. D, TBMD in 14 female adrenalectomized patients
vs. TBMD in their individual controls.
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FIG. 2. Difference in %BF between the two methods (alternatives A–E against the 4C-model according to Füller) plotted against the means.
Indicated is the mean difference (bias) and 2 SD (error). A, UWW; B, D2O dilution method; C, DXA; D, skinfold measurements; E, BIS.
3996 KEMINK ET AL. JCE & M • 1999
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other hand, results from the descriptive methods, skinfold
measurement and BIS, deviated substantially from results
using the 4C-model. With respect to skinfold measurement,
this deviation probably can be attributed to the peculiar body
fat distribution in the patients. As patients have relatively
more truncal body fat, skinfold measurements, of which only
the iliac is in the truncal region, underestimated the %BF in
the patient group. Plotting of the difference in %BF between
the skinfold and the 4C-model against their means showed
a significant correlation between both the difference and the
mean. This discloses a disagreement between the methods.
The higher the mean %BF, the larger the discrepancy be-
tween the two methods. Comparison between the results
from BIS and the 4C-model also reveals a significant corre-
lation between the difference in %BF by both BIS and the
4C-model, on one hand, and the mean %BF, on the other
hand. In our study total body water volumes were calculated
from a general mixture theory (10, 11), using specific resis-
tivities of the water compartments, rather than applying the
common procedure in bioimpedance analyses of an empir-
ically determined regression equation. The disagreement be-
tween the results from BIS and the 4C-model can be ex-
plained by these specific resistivities. It is, however,
important to realize that these coefficients do not affect the
correlation between the methods. The relation between the
error and the mean of the measurements can be caused by
differences in body shape or fat distribution, as with the
skinfold measurements. On the other hand, specific resis-
tivities of the water compartments may be different between
patients and controls. From these data we conclude that
UWW, DXA, and D2O dilution can be used for assessing the
%BF in adrenalectomized patients. The two more convenient
bedside methods, BIS and skinfold measurements, did not
give reliable results.
Several explanations may be offered for the increased %BF
and truncal obesity in the former Cushing’s patients. Hypo-
thyroidism as the cause of the increased %BF is unlikely.
Although four patients had secondary hypothyroidism after
pituitary surgery, they were adequately substituted with
levothyroxine, having plasma free T4 levels in the normal
range. In the other patients euthyroidism was documented.
Furthermore, six patients were treated with oral and one
with transdermal estrogens as contraceptive or replacement
therapy, whereas in the control group only two women used
estrogens. It is unlikely, however, that the use of estrogens
could be responsible for the centripetal obesity in the patient
group. In postmenopausal women estrogen replacement
therapy is not associated with weight gain and central obe-
sity (15, 16). In fact, estrogen replacement reduces the in-
crease of the waist to hip ratio after the menopause (17). In
premenopausal women the use of modern oral contraceptive
agents, containing less than 50 mg ethinyl estradiol, is also not
associated with weight gain (18, 19).
GH deficiency can cause increased body fat mass in adults
(20–22). As 10 of the 14 patients had undergone pituitary
surgery for Cushing’s disease or Nelson’s syndrome, it is
conceivable that some of them were GH deficient. At present,
the biochemical criteria for the diagnosis of GH deficiency in
adulthood are not firmly established and are restricted to
individuals less than 50 yr old (23, 24). For severe GH de-
ficiency in premenopausal women, De Boer et al. (25) pro-
posed to use a cut-off level for plasma GH of less than 15
mU/L after provocation with arginine (0.5 g/kg BW). In our
study, only 4 of the 13 tested patients had an arginine-stim-
ulated peak plasma GH level greater than 15 mU/L. It re-
mains, however, uncertain whether the other patients are GH
deficient, as 8 of them were postmenopausal and older than
50 yr of age. With aging, a substantial decrease in GH re-
sponsiveness is present (25), and there are no reliable criteria
for GH deficiency in this group. Furthermore, decreased
spontaneous GH secretion and subnormal GH responsive-
ness are characteristic findings in obese subjects (25) as well
as in subjects treated with glucocorticoids, at least in high
doses (26, 27). However, when we used a cut-off level of 15
or 10 mU/L with regard to the arginine-stimulated peak
plasma GH, there was no difference in %BF and fat distri-
bution between the groups with the higher and the lower GH
responses. Therefore, although it cannot be excluded that in
some patients GH deficiency may play a contributory role,
GH deficiency is unlikely to be the most important cause of
the increased %BF and truncal obesity in the adrenalecto-
mized patients.
In our opinion the truncal obesity in the adrenalectomized
patients is most likely the result of glucocorticoid overre-
placement. In patients with Cushing’s syndrome, hypercor-
tisolism is associated with an excess of visceral and sc ab-
dominal fat. It has been suggested that this is caused by the
high density of glucocorticoid receptors in this depot (28, 29).
There is evidence that cortisol may exert its effect by raising
lipoprotein lipase activity. In differentiated human adipo-
cytes as well as in human fat cells in vitro, glucocorticoids
enhanced lipoprotein lipase activity, and this effect was
TABLE 4. Comparison of body composition techniques with the reference technique (4C model); regression analyses of the difference
between respective methods and their mean
R2 P Bias (averagedifference) Error (2 SD, 95% CI) P
UWW NS 20.65 3.6 NS
D2O dilution NS 23.2 2.4 ,0.05
DXA NS 21.98 5.8 NS
BIS 0.54 ,0.0001
Skinfolds 0.46 ,0.0004
Given are the regression coefficient (R2) and P value. When there was no significant relation, bias (average difference between the methods)
and error (2 SD or 95% CI) are presented. 4C model, Four-component model; UWW, underwater weighing; D2O dilution, deuterium dilution
method; DXA, dual energy x-ray absorptiometry; BIS, bioelectrical impedance spectrometry; skinfolds, skinfold measurements. The statistically
significant regression coefficients of BIS and skinfolds disclose a significant relation between the differences in percent body fat of the two
methods compared to the 4C model and the size of the measurement. This relation is compatible with disagreement between methods.
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probably mediated by glucocorticoid receptors (28). Wa-
jchenberg et al. (30) studied body composition data deter-
mined by DXA and the abdominal visceral fat component
determined by computed tomographic scanning in women
with Cushing’s disease and compared these data with those
from obese women with the same anthropometric parame-
ters. Although patients with Cushing’s disease had no in-
crease in total body fat, they had a higher intraabdominal fat
area compared to the obese subjects. The total lean tissue
mass was slightly reduced in the patients with Cushing’s
disease compared to that in the obese subjects due to a
significant decrease in the muscles of the legs and arms. Lönn
et al. (31) reported that pituitary surgery in women with
Cushing’s disease resulted in a reduction of the total body fat
mass. Furthermore, a change in body fat distribution was
demonstrated by expressing regional fat mass depots as a
percentage of the total body fat mass before and after treat-
ment. After pituitary surgery, the visceral fat mass and sc fat
mass of the trunk decreased, which was significantly differ-
ent from the increase in the fat mass of the legs.
In the adrenalectomized patients in our study, the dosage
of glucocorticoids, on the average, 27.3 mg hydrocortisone
equivalents/day, although conventionally considered a near
optimal amount (32), still might be too high to resolve typical
Cushing’s symptoms, such as truncal obesity and muscle
wasting. None of these 14 patients showed other clinical
signs of overtreatment with glucocorticoids. Unfortunately,
we do not have body composition data in untreated Cush-
ing’s disease patients, nor have such data been reported in
literature. Moreover, similar data in patients successfully
treated by pituitary adenomectomy are lacking.
Other researchers also found arguments for overreplace-
ment with glucocorticoids, in dosages similar to those used
in our study, in patients with primary or secondary adrenal
insufficiency. Peacy et al. (33) studied 32 patients receiving
glucocorticoid therapy, 12 with Addison’s disease and 20
with hypopituitarism. Aiming at peak serum cortisol levels
and 24-h urinary free cortisol levels in the normal reference
range and avoiding prolonged cortisol troughs, 88% of the
patients required a reduction of the daily glucocorticoid dose
and/or a change in glucocorticoid regimen. The mean daily
dose of hydrocortisone in this group had to be reduced from
29.5 6 1.2 to 20.8 6 1.0 mg to achieve adequate serum cortisol
and urinary free cortisol levels. Howlett (34) surveyed case
notes of 130 patients receiving glucocorticoid replacement
therapy. Considering serum cortisol and urinary free cortisol
levels, he concluded that optimal replacement best might be
achieved with doses of 20 mg hydrocortisone in 3 divided
doses. From these studies, unfortunately, no body compo-
sition data for the patients are available.
Whereas the body composition of the patients suggests
overdosage of substituting glucocorticoids, bone density
data did not differ between the substituted patients and the
healthy controls. In a recent study in Dutch Addisonians
using similar dosages of glucocorticoids as those used by our
adrenalectomized women, BMD was significantly lower in
the male patients compared to the control subjects, whereas
there was no difference in BMD between female Addisonians
and controls (35). In the men with decreased BMD, the daily
hydrocortisone dose per kg BW appeared significantly
higher than in men with normal BMD. The researchers sug-
gested that estrogen activity in the females might have pre-
vented glucocorticoid-induced osteopenia. In the study by
Peacey et al. (33), BMD at the lumbar spine was significantly
lower in a group of 32 patients (13 men and 19 women)
receiving glucocorticoid replacement therapy than in age-
and sex-matched controls. A weak, but significant, negative
correlation was found between BMD and the daily dose of
hydrocortisone, expressed as milligrams per kg. Moreover,
patients with higher serum cortisol and 24-h urinary free
cortisol levels had significantly lower osteocalcin levels. In
the patients whose glucocorticoid dose was reduced during
the study, the osteocalcin concentration increased signifi-
cantly, demonstrating that even small changes in cortisol
replacement therapy may lead to a change in bone formation.
From their data it can be assumed that even mildly excessive
glucocorticoid replacement has adverse effects on bone for-
mation and BMD, at least in men. The risk of bone loss during
long term treatment with standard replacement doses is an-
other argument for adjustment of glucocorticoid therapy to
the lowest acceptable dose.
In conclusion, measurements of body composition in our
adrenalectomized patients receiving conventional glucocor-
ticoid substitution showed a markedly increased %BF with
a relatively high amount of truncal body fat and a decreased
FFM, whereas BMD was normal. Comparison of body com-
position measurement methods indicated that rather sophis-
ticated methods, such as DXA, UWW, or D2O dilution, are
necessary to reliably assess body composition in these pa-
tients. More convenient bedside methods, such as BIS and
skinfold measurements, did not give reliable body compo-
sition data. Although we cannot exclude that GH deficiency
might have played a role in some patients, in our opinion the
centripetal obesity of the adrenalectomized patients is most
likely the result of glucocorticoid overreplacement.
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